New Parkinson's pill aims to cut 'OFF' time and ease daily struggles

NCT ID NCT07514858

Not yet recruiting Symptom relief Sponsor: H. Lundbeck A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding Lu AF28996 to standard Parkinson's medications can extend the time patients feel their movement symptoms are well-controlled (called 'good ON time'). About 150 adults with Parkinson's who still experience motor fluctuations despite optimized treatment will receive either the drug or a placebo. The main goal is to see if the drug increases daily good ON time without troublesome dyskinesia over 19 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lu AF28996
What this could lead to: If successful, this could provide a new add-on medication to help Parkinson's patients spend more time with well-controlled movement symptoms and less time in 'OFF' periods.
What could go wrong: This is an early Phase 2 trial with only 150 participants, so results may not confirm benefit. The drug may cause side effects or fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.